CellaVision AB (publ) (STO:CEVI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 2.97B -37.8% |
| Revenue (ttm) | 730.59M -2.3% |
| Net Income | 134.07M -11.9% |
| EPS | 5.62 -11.9% |
| Shares Out | 23.85M |
| PE Ratio | 22.13 |
| Forward PE | 19.47 |
| Dividend | 2.75 (2.25%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 16,460 |
| Average Volume | 68,675 |
| Open | 122.60 |
| Previous Close | 122.00 |
| Day's Range | 122.60 - 125.80 |
| 52-Week Range | 117.60 - 202.50 |
| Beta | 0.95 |
| RSI | 42.03 |
| Earnings Date | Jul 17, 2026 |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and Cella... [Read more]
Financial Performance
In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.
Financial StatementsNews
CellaVision AB (CLVSF) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
CellaVision AB (CLVSF) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
CellaVision AB Earnings Call Transcript: Q1 2026
Q1 revenue fell 14.6% year-over-year due to EMEA inventory adjustments, while Americas and APAC delivered strong growth. New product launches and a major software upgrade are expected to drive H2 recovery, with EMEA sales seen improving in Q2.
CellaVision AB Quarterly report: Q1 2026
CellaVision AB has published its Q1 2026 quarterly earnings report on April 24, 2026.
CellaVision AB Earnings Call Transcript: Q1 2026
Q1 revenue fell 14.6% year-over-year due to EMEA inventory adjustments, while Americas and APAC delivered strong growth. New product launches and a major software upgrade are expected to drive H2 recovery, with EMEA sales seen improving in Q2.
CellaVision AB Quarterly report: Q1 2026
CellaVision AB has published its Q1 2026 quarterly earnings report on April 24, 2026.
CellaVision AB Earnings Call Transcript: Q4 2025
Q4 2025 saw robust growth in the Americas and EMEA, offsetting a softer APAC, with full-year organic growth at 9%. Strategic milestones included a CE Mark for the bone marrow application and a major software upgrade, while a dividend increase to SEK 2.75 per share is proposed.
CellaVision AB Annual report: Q4 2025
CellaVision AB has published its Q4 2025 annual report on February 5, 2026.
CellaVision AB Quarterly report: Q4 2025
CellaVision AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
CellaVision AB Slides: Q4 2025
CellaVision AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
CellaVision AB Earnings Call Transcript: Q4 2025
Q4 2025 saw robust growth in the Americas and EMEA, offsetting a softer APAC, with full-year organic growth at 9%. Strategic milestones included a CE Mark for the bone marrow application and a major software upgrade, while a dividend increase to SEK 2.75 per share is proposed.
CellaVision AB Annual report: Q4 2025
CellaVision AB has published its Q4 2025 annual report on February 5, 2026.
CellaVision AB Quarterly report: Q4 2025
CellaVision AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
CellaVision AB Slides: Q4 2025
CellaVision AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
CellaVision AB Earnings Call Transcript: Q3 2025
Net sales declined 1.7% to SEK 176 million, but organic growth was 2.6% year-over-year, with EBITDA margin rising to 28%. Strategic milestones include a completed clinical trial and software upgrade, while regional performance was mixed and APAC showed lumpy but positive trends.
CellaVision AB Quarterly report: Q3 2025
CellaVision AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
CellaVision AB Slides: Q3 2025
CellaVision AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
CellaVision AB Earnings Call Transcript: Q3 2025
Net sales declined 1.7% to SEK 176 million, but organic growth was 2.6% year-over-year, with EBITDA margin rising to 28%. Strategic milestones include a completed clinical trial and software upgrade, while regional performance was mixed and APAC showed lumpy but positive trends.
CellaVision AB Quarterly report: Q3 2025
CellaVision AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
CellaVision AB Slides: Q3 2025
CellaVision AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
CellaVision AB Earnings Call Transcript: Q2 2025
Q2 2025 saw robust results with SEK 191 million revenue and nearly 8% organic growth, led by APAC. Gross margin rose to 68%, and EBITDA margin was 31%. Strategic launches and R&D investments continue, with the bone marrow module set for 2026 commercial launch.
CellaVision AB Quarterly report: Q2 2025
CellaVision AB has published its Q2 2025 quarterly earnings report on July 18, 2025.
CellaVision AB Slides: Q2 2025
CellaVision AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 18, 2025.
CellaVision AB Earnings Call Transcript: Q2 2025
Q2 2025 saw robust results with SEK 191 million revenue and nearly 8% organic growth, led by APAC. Gross margin rose to 68%, and EBITDA margin was 31%. Strategic launches and R&D investments continue, with the bone marrow module set for 2026 commercial launch.
CellaVision AB Quarterly report: Q2 2025
CellaVision AB has published its Q2 2025 quarterly earnings report on July 18, 2025.
CellaVision AB Slides: Q2 2025
CellaVision AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 18, 2025.